Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2022; 10(4): 1164-1171
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1164
Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
Zhi-Quan Qin, Si-Fu Yang, Yun Chen, Chao-Jin Hong, Tong-Wei Zhao, Guo-Rong Yuan, Liu Yang, Liang Gao, Xiao Wang, Li-Qin Lu
Zhi-Quan Qin, Si-Fu Yang, Yun Chen, Chao-Jin Hong, Tong-Wei Zhao, Guo-Rong Yuan, Liu Yang, Liang Gao, Xiao Wang, Li-Qin Lu, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China
Author contributions: Qin ZQ and Yang SF designed and performed the research and wrote the paper; Chen Y, Hong CJ and Zhao TW designed the research and supervised the report; Yuan GR and Yang L designed the research and contributed to the analysis; Gao L and Wang X provided clinical advice; Lu LQ supervised the report; all authors gave final approval for the version to be submitted.
Institutional review board statement: This study was reviewed and approved by the ethics committee of Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College) (2021QT290).
Informed consent statement: The ethics committee of Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College) waived the requirement for written informed patient consent, because this was a retrospective analysis based on the assessment of medical records.
Conflict-of-interest statement: The authors declared no conflicts of interest for this manuscript.
Data sharing statement: No additional data were available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Qin Lu, MD, Professor, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. llq199@outlook.com
Received: September 15, 2021
Peer-review started: September 15, 2021
First decision: October 18, 2021
Revised: October 27, 2021
Accepted: December 22, 2021
Article in press: December 22, 2021
Published online: February 6, 2022
Core Tip

Core Tip: Lung cancer is one of the malignancies with the highest incidence and mortality worldwide. However, the efficacy and safety of the current regimens is unsatisfactory. Therefore, the development and upgrade of potential therapies that are more effective and less toxic is warranted. This is a retrospective study to investigate the efficacy and safety of 5-d continuous intravenous infusion of Recombinant human endostatin (Rh-endostain) in advanced non-small cell lung cancer (NSCLC) patients. Our results revealed that 5-day continuous intravenous infusion of Rh-endostain using infusion pump improved patient adherence and showed favorable efficacy and safety, which brought significant clinical benefits to advanced NSCLC patients.